Herb drug interaction: effect of Manix® on pharmacokinetic parameters of pefloxacin in rat model

<p><b>OBJECTIVE</b>To evaluate the effect of Manix®, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.</p><p><b>METHODS</b>Microbiological assay was employed using clinical isolate of Escherichia coli samples from hospitalized patients.</p><p><b>RESULTS</b>Manix® altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) µg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix® alongside pefloxacin Cmax was (0.22±0.08) µg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) µg/h/mL while with Manix® was (2.60±0.08) µg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix® pre-treatment (P<0.05).</p><p><b>CONCLUSIONS</b>The concurrent use of Manix® and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.</p>

Herb drug interaction：effect of Manix? on pharmacokinetic parameters of pefloxacin in rat model

Objective: To evaluate the effect of Manix?, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.Methods:from hospitalized patients.Results:Microbiological assay was employed using clinical isolate of Escherichia coli samples Manix? altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) μg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix? alongside pefloxacin Cmax was (0.22±0.08) μg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) μg/h/mL while with Manix? was (2.60±0.08) μg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix? pre-treatment (P<0.05).Conclusions:The concurrent use of Manix? and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.